مباشر

Clinical OMICsMacrophage EGFR Activity Linked to Immune Suppression, Tumor Growth in Colorectal Cancer Clinical OMICsUnexpected Role for RNA Editing in Cancer Immune Evasion Uncovered Clinical OMICsProactive Surveillance Pays Off for Patients with Li-Fraumeni Syndrome Clinical OMICsCAR T Success Hinges on Microenvironment Response in GBM Endpoints NewsFDA warns telehealth companies over compounded GLP-1s BioPharma DiveUniQure to file gene therapy for approval, reflecting major shifts at FDA Endpoints NewsUK waitlist for Novo's Wegovy pill triples in week after approval, major online pharmacy says Endpoints NewsHackers claim they stole Novo Nordisk AI models, manufacturing recipes Endpoints NewsIn second reversal, FDA gives uniQure a green light to seek accelerated approval BioPharma DiveJazz zeroes in on next-gen T cell engagers with AbCellera deal Clinical OMICsVibrating Pill Predicts Anorexia Relapse BioWorldFlexibility restored? Uniqure plans for BLA filing in Huntington’s

BioPharma Dive ١٧ يونيو ٢٠٢٦

Jazz zeroes in on next-gen T cell engagers with AbCellera deal

The potentially $4 billion collaboration is the latest example of drugmakers working to broaden the use of T cell engagers, which, so far, have had limited succ...

The potentially $4 billion collaboration is the latest example of drugmakers working to broaden the use of T cell engagers, which, so far, have had limited success outside of certain blood cancers.